← Back to Clinical Trials
Recruiting NCT06934421

NCT06934421 Revised Targets for Knee Radiofrequency Ablation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06934421
Status Recruiting
Phase
Sponsor Centro Hospitalar Universitario do Algarve
Condition Osteoarthritis Knee Pain
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2025-03-20
Primary Completion 2028-07-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Ultrasound-Guided Genicular Nerve Radiofrequency Ablation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2025-03-20 with a primary completion date of 2028-07-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research team is doing a study to learn more about a new way to treat long-term knee pain caused by joint damage. They are using a treatment called radiofrequency ablation (RFA). This is a procedure where doctors use heat to stop certain nerves from sending pain signals. In this study, doctors will use ultrasound to guide a small needle to nerves around the knee, called genicular nerves. Then, they will apply heat to those nerves using radiofrequency energy to help reduce pain. The team created this new method based on recent studies of knee anatomy. They want to find out if this method can safely reduce pain and help people with knee joint damage move better. The study includes people who have moderate to severe knee damage and still have pain after trying medicine, physical therapy, or joint injections. Each person in the study will have the treatment once. The research team will follow each person for two years. During this time, people in the study will answer simple questions about their knee pain and how it affects their daily life. The researchers will collect this information before the treatment and several times after it. One week after the procedure, the team will call each person to ask how they are feeling and check for any side effects. Possible benefits of the study include less knee pain and easier movement. Possible risks include pain during the procedure, bruising, swelling, or short-term worsening of pain. Rare risks include nerve problems, weakness, bone damage, or allergic reaction. The study is free for participants, and there is no payment. Taking part is voluntary. Anyone can stop being in the study at any time without affecting their medical care. The research team will keep all personal information private and secure.

Eligibility Criteria

Inclusion Criteria: * Patients with chronic knee pain related to radiographic knee osteoarthritis, Kellgren-Lawrence (KL) grade III or IV, who are refractory to conservative treatment. (Refractoriness to conservative treatment is defined as: * Persistent pain and functional limitation after undergoing knee-targeted physiotherapy and analgesic medication in accordance with clinical guidelines for osteoarthritis \[e.g., paracetamol, nonsteroidal anti-inflammatory drugs, and other drugs as deemed appropriate by the treating physician\]; * Persistent pain and functional limitation after intra-articular corticosteroid injections or limited success with such interventions.) Exclusion Criteria: * Patients with previous knee arthroplasty * Patients who have undergone prior radiofrequency (RF) ablation * Significant psycho-emotional disorders * Addictive behaviors * Generalized pain * Nociplastic pain * Presence of a pacemaker * Presence of osteosynthesis material in the knee or adjacent anatomical regions

Contact & Investigator

Central Contact

Manuel Tomás Farinha Caroço, Medical Doctor

✉ farinhacaroco@gmail.com

📞 +351968010683

Principal Investigator

Manuel Tomás Farinha Caroço, Medical Doctor

PRINCIPAL INVESTIGATOR

Unidade Local de Saude do Algarve / Centro Hospitalar Universitario Algarve

Frequently Asked Questions

Who can join the NCT06934421 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Osteoarthritis Knee Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06934421 currently recruiting?

Yes, NCT06934421 is actively recruiting participants. Contact the research team at farinhacaroco@gmail.com for enrollment information.

Where is the NCT06934421 trial being conducted?

This trial is being conducted at Faro, Portugal, Lisbon, Portugal.

Who is sponsoring the NCT06934421 clinical trial?

NCT06934421 is sponsored by Centro Hospitalar Universitario do Algarve. The principal investigator is Manuel Tomás Farinha Caroço, Medical Doctor at Unidade Local de Saude do Algarve / Centro Hospitalar Universitario Algarve. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology